Ubiquitin Chains: Degradation and Beyond

di Arnab De
Stato: Nuovo
94,87 €
IVA inclusa - Spedizione GRATUITA
Arnab De Ubiquitin Chains: Degradation and Beyond
Arnab De - Ubiquitin Chains: Degradation and Beyond

Ti piace questo prodotto? Condividilo con i tuoi amici!

94,87 € IVA inclusa
Solo 1 articolo rimasto Solo 1 articoli rimasti Più di 10 pezzi disponibili
Consegna: tra martedì 5 luglio 2022 e giovedì 7 luglio 2022
Vendita & spedizione: Dodax

Altre opzioni di acquisto

1 offerta a 94,88 €

Venduto da Dodax

94,88 € IVA inclusa
Stato: Nuovo
Spedizione gratuita
Consegna: tra martedì 5 luglio 2022 e giovedì 7 luglio 2022
Visualizza altre opzioni di acquisto

Descrizione

This thesis examines the evidence for regulatory ubiquitination by focusing on A20. It provides an insightful and in-depth evaluation of the current literature by critically examining the evidence of K63-linked regulatory ubiquitination in regulating cell-signalling. It is also the first thesis to directly test the role of regulatory ubiquitination in NF-kB signaling in vivo. The case for regulatory ubiquitination has been to a large extent predicated upon the presumed deubiquitinase activity of A20, long considered a key regulator of inflammatory responses as mice lacking A20 die from multi-organ inflammation and cachexia. The theses reports the creation and characterization of a knock-in mouse that expresses a mutated form of A20 which selectively lacks the deubiquitinase activity. The knock-in mice surprisingly display completely normal NF-κB activation with no accompanying inflammatory phenotype. Given that the presumed role of A20 as a deubiquitinase has been used to support the importance of regulatory K63-linked ubiquitination in NF-kB signaling, this study will help focus future research efforts into alternative target pathways that do not depend on K63 ubiquitination. In fact, the work suggests that it might be important to revisit the role of K63-linked polyubiquitination in cell-signalling. Ubiquitin Chains: Degradation and Beyond is essential reading for anyone conducting research in cell-signalling and immunology.
Dr. Arnab De received his PhD from the Department of Microbiology & Immunology at Columbia University. During his PhD, he developed transgenic mice to study the mechanism of action of a critical tumor-suppressor called A20. He is also well known for having developed peptide-based prodrugs as therapeutics for diabetes. His work has been reported by the media, and has resulted in multiple patents and publications in peer reviewed journals. He presented his findings at the American Peptide Symposium and was awarded the Young Investigator’s Award. He is the author of the book entitled Application of Peptide-Based Prodrug Chemistry in Drug Development, with a foreword written by Professor Jean Martinez (Former President, European Peptide Society) and published in the series SpringerBriefs in Pharmaceutical Science & Drug Development. His research interests lie at the intersection of chemistry and medicine.  Besides biomedical research, he is also generally interested in public health policy and general scientific outreach.

Contributori

Scrittore:
Arnab De

Ulteriori informazioni

Illustrations Note:
XV, 103 p. 45 illus., 33 illus. in color.
Indice:
.- 1 Immune homeostasis: Activation and Downregulation of NF-κB.- 2 Regulation of NF-κB signaling by regulatory ubiquitination: specific pathways and A20.- 3 The deubiquitinase activity of A20 is dispensable for its role in NF-κB signaling.- 4 Perspectives on regulatory ubiquitination.
Commenti:
Nominated as an outstanding Ph.D. thesis by Columbia University, New York, USA


Insightful and in-depth evaluation of the evidence for K63-linked regulatory ubiquitination in regulating cell-signalling in vitro


First theses to directly test the role of regulatory ubiquitination in NF-kB signaling in vivo


Reports the generation of a knock-in mouse that expresses a mutated form of A20 selectively lacking the deubiquitinase activity


Critically determines the role of the deubiquitinase function of A20 in limiting inflammatory responses in vivo

Tipo multimediale:
Copertina morbida
Editore:
Springer International Publishing
Biografia:
Dr. Arnab De received his PhD from the Department of Microbiology & Immunology at Columbia University. During his PhD, he developed transgenic mice to study the mechanism of action of a critical tumor-suppressor called A20. He is also well known for having developed peptide-based prodrugs as therapeutics for diabetes. His work has been reported by the media, and has resulted in multiple patents and publications in peer reviewed journals. He presented his findings at the American Peptide Symposium and was awarded the Young Investigator’s Award. He is the author of Application of Peptide-Based Prodrug Chemistry in Drug Development, with a foreword written by Professor Jean Martinez (Former President, European Peptide Society) and published in the series SpringerBriefs in Pharmaceutical Science & Drug Development. His research interests lie at the intersection of chemistry and medicine.  Besides biomedical research, he is also generally interested in public health policy and general scientific outreach.
Lingua:
Inglese
Edizione:
Softcover reprint of the original 1st ed. 2015
Numero di Pagine:
103

Dati Principali

Tipologia prodotto:
Brossura
Data di pubblicazione:
9 ottobre 2016
Dimensioni del collo:
0.235 x 0.155 x 0.007 m; 0.454 kg
GTIN:
09783319385341
DUIN:
RCVFPVOTD7N
94,87 €
Utilizziamo i cookie sul nostro sito Web per rendere la tua visita più efficiente e più user-friendly. Per assicurarti di poter utilizzare tutte le funzioni presenti, fai clic su "accetta cookie". Per ulteriori informazioni, consulta la nostra Informativa sulla privacy.